Physician profile
Peter M Gottesfeld
NPI 1114011368
$16,591.23
in general payments reported to CMS, 2019-2025
19 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,966 · 2020: $5,118 · 2021: $1,305 · 2022: $599 · 2023: $235 · 2024: $234 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13,960.44 | 2019-2022 | |
| Abbvie INC. | $581.43 | 2021-2024 | |
| Amgen INC. | $525.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $278.73 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $236.34 | 2019-2025 | Breztri |
| Kowa Pharmaceuticals America, INC. | $208.98 | 2020-2024 | Livalo |
| Endo Pharmaceuticals INC. | $129.08 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.50 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $106.85 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.87 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $55.12 | 2019-2020 | |
| Astellas Pharma US INC | $45.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.27 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.76 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.69 | 2019 | |
| Genentech USA, INC. | $20.36 | 2020 | |
| Circassia INC. | $18.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gottesfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.